Searching for animal models and potential target species for emerging pathogens: Experience gained from Middle East respiratory syndrome (MERS) coronavirus

One Health

Volumn 3, Issue , 2017, Pages 34-40

  Vergara Alert, Júlia ^a   Vidal, Enric ^a   Bensaid, Albert ^a   Segalés, Joaquim ^b,c  

^a IRTA   (Spain)

^b CENTRE DE RECERCA EN SANITAT ANIMAL CRESA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Animal model; Coronavirus (CoV); Emerging pathogen; Middle East respiratory syndrome (MERS); Reservoir

Indexed keywords

ALPACA; BIOSAFETY; CALLITRICHINAE; CAMEL; CAMELID; DISEASE CARRIER; DISEASE MODEL; DISEASE SURVEILLANCE; DOMESTIC ANIMAL; DROMEDARY CAMEL; HOST; HOST RANGE; HOST SELECTION; HOST SUSCEPTIBILITY; IMMUNOLOGICAL MONITORING; INFECTION SENSITIVITY; LLAMA; MEDICAL RESEARCH; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NON CAMELID DOMESTIC SPECIES; NON HUMAN PRIMATE; NONHUMAN; PATHOGENESIS; PRIMATE; REVIEW; RHESUS MONKEY; VIRAL PATHOGENESIS; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 85014788827     PISSN: None     EISSN: 23527714     Source Type: Journal    
DOI: 10.1016/j.onehlt.2017.03.001     Document Type: Review

References (66)

1. [1] Rubin, C., Myers, T., Stokes, W., Dunham, B., Harris, S., Lautner, B., et al. Review of institute of medicine and national research council recommendations for one health initiative. Emerg. Infect. Dis. 19:12 (2013), 1913–1917.
2. [2] Jones, K.E., Patel, N.G., Levy, M.A., Storeygard, A., Balk, D., Gittleman, J.L., et al. Global trends in emerging infectious diseases. Nature 451:7181 (2008), 990–993.
3. [3] Morse, S.S., Mazet, J.A.K., Woolhouse, M., Parrish, C.R., Carroll, D., Karesh, W.B., et al. Prediction and prevention of the next pandemic zoonosis. Lancet 380:9857 (2012), 1956–1965.
4. [4] Mäkelä, M.J., Puhakka, T., Ruuskanen, O., Leinonen, M., Saikku, P., Kimpimäki, M., et al. Viruses and bacteria in the etiology of the common cold. J. Clin. Microbiol. 36:2 (1998), 539–542.
5. [5] World Health Organization, WHO, http://www.who.int/csr/don/2016_, 2014 (Accessed on December 15, 2016).
6. [6] Bermingham, A., Chand, M.A., Brown, C.S., Aarons, E., Tong, C., Langrish, C., et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to United Kingdom from the Middle East, September 2012. Euro Surveill., 17(40), 2012, 20290.
7. [7] World Health Organization, WHO, http://www.who.int/emergencies/mers-cov/en/, 2016 (Accessed on December 15, 2016).
8. [8] World Health Organization, WHO, https://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/, 2014 (Accessed on December 15, 2016).
9. [9] Paweska, J.T., Sewlall, N.H., Ksiazek, T.G., Blumberg, L.H., Hale, M.J., Lipkin, W.I., et al. Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg. Infect. Dis. 15:10 (2009), 1598–1602.
10. [10] Yu, X.J., Liang, M.F., Zhang, S.Y., Liu, Y., Li, J.D., Sun, Y.L., et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N. Engl. J. Med. 364:16 (2011), 1523–1532.
11. [11] Safronetz, D., Geisbert, T.W., Feldmann, H., Animal models for highly pathogenic emerging viruses. Curr. Opin. Virol. 3:2 (2013), 205–209.
12. [12] Food and Drug Administration, FDA, Guidance for industry product development under the animal rule. US Department of Health and Human Services, May 2014 ed., 2014, FDA, Silver Spring, MD.
13. [13] Plumb, G., Babiuk, L., Mazet, J., Olsen, S., Rupprecht, C., Pastoret, P.P., et al. Vaccination in conservation medicine. Rev. Sci. Tech. 26:1 (2007), 229–241.
14. [14] Adams, L.G., Khare, S., Lawhon, S.D., Rossetti, C.A., Lewin, H.A., Lipton, M.S., et al. Enhancing the role of veterinary vaccines reducing zoonotic diseases of humans: linking systems biology with vaccine development. Vaccine 29:41 (2011), 7197–7206.
15. [15] Alharbi, N.K., Vaccines against Middle East respiratory syndrome coronavirus for humans and camels. Rev. Med. Virol., 2016 Oct 27, 10.1002/rmv.1917 (Epub ahead of print).
16. [16] Lowenthal, J., Overview of the CSIRO Australian Animal Health Laboratory. J. Infect. Public Health 9:3 (2016 May–Jun), 236–239.
17. [17] Baseler, L.J., Falzarano, D., Scott, D.P., Rosenke, R., Thomas, T., Munster, V.J., et al. An acute immune response to Middle East respiratory syndrome coronavirus replication contributes to viral pathogenicity. Am. J. Pathol. 186:3 (2016), 630–638.
18. [18] van Doremalen, N., Munster, V.J., Animal models of Middle East respiratory syndrome coronavirus infection. Antivir. Res. 122 (2015), 28–38.
19. [19] Sutton, T.C., Subbarao, K., Development of animal models against emerging coronaviruses: from SARS to MERS coronavirus. Virology 479–480 (2015), 247–258.
20. [20] Baseler, L., de Wit, E., Feldmann, H., A comparative review of animal models of Middle East respiratory syndrome coronavirus infection. Vet. Pathol. 53:3 (2016), 521–531.
21. [21] de Wit, E., Rasmussen, A.L., Falzarano, D., Bushmaker, T., Feldmann, F., Brining, D.L., et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc. Natl. Acad. Sci. U. S. A. 110:41 (2013), 16598–16603.
22. [22] Munster, V.J., de Wit, E., Feldmann, H., Pneumonia from human coronavirus in a macaque model. N. Engl. J. Med. 368:16 (2013), 1560–1562.
23. [23] Yao, Y., Bao, L., Deng, W., Xu, L., Li, F., Lv, Q., An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus. J. Infect. Dis. 209:2 (2014), 236–242.
24. [24] Falzarano, D., de Wit, E., Feldmann, F., Rasmussen, A.L., Okumura, A., Peng, X., et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog., 10(8), 2014, e1004250.
25. [25] Raj, V.S., Mou, H., Smits, S.L., Dekkers, D.H., Müller, M.A., Dijkman, R., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495:7440 (2013), 251–254.
26. [26] Wang, N., Shi, X., Jiang, L., Zhang, S., Wang, D., Tong, P., et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 23:8 (2013), 986–993.
27. [27] de Wit, E., Prescott, J., Baseler, L., Bushmaker, T., Thomas, T., Lackemeyer, M.G., et al. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS One, 8(7), 2013, e69127.
28. [28] Coleman, C.M., Matthews, K.L., Goicochea, L., Frieman, M.M., Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J. Gen. Virol. 95:Pt 2 (2014), 408–412.
29. [29] Zhao, J., Li, K., Wohlford-Lenane, C., Agnihothramn, S.S., Fett, C., Zhao, J., et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl. Acad. Sci. U. S. A. 111:13 (2014), 4970–4975.
30. [30] Agrawal, A.S., Garron, T., Tao, X., Peng, B.H., Wakamiya, M., Chan, T.S., et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J. Virol. 89:7 (2015), 3659–3670.
31. [31] Houdebine, L.M., Transgenic animal models in biomedical research. Methods Mol. Biol. 360 (2007), 163–202.
32. [32] Peck, K.M., Cockrell, A.S., Yount, B.L., Scobey, T., Baric, R.S., Heise, M.T., Glycosylation of mouse DPP4 plays a role in inhibiting Middle East respiratory syndrome coronavirus infection. J. Virol. 89:8 (2015), 4696–4699.
33. [33] Cockrell, A.S., Yount, B.L., Scobey, T., Jensen, K., Douglas, M., Beall, A., et al. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat Microbiol., 2, 2016, 16226.
34. [34] Tai, W., Zhao, G., Sun, S., Guo, Y., Wang, Y., Tao, X., et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology 499 (2016), 375–382.
35. [35] Qiu, H., Sun, S., Xiao, H., Feng, J., Guo, Y., Tai, W., et al. Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection. Antivir. Res. 132 (2016), 141–148.
36. [36] Pascal, K.E., Coleman, C.M., Mujica, A.O., Kamat, V., Badithe, A., Fairhurst, J., et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc. Natl. Acad. Sci. U. S. A. 112:28 (2015), 8738–8743.
37. [37] de Benedictis, P., Marciano, S., Scaravelli, D., Priori, P., Zecchin, B., Capua, I., et al. Alpha and lineage C beta CoV infections in Italian bats. Virus Genes 48:2 (2014), 366–371.
38. [38] Memish, Z.A., Mishra, N., Olival, K.J., Fagbo, S.F., Kapoor, V., Epstein, J.H., et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg. Infect. Dis. 19:11 (2013), 1819–1823.
39. [39] Munster, V.J., Adney, D.R., van Doremalen, N., Brown, V.R., Miazgowicz, K.L., Milne-Price, S., et al. Replication and shedding of MERS-CoV in Jamaican fruit bats (Artibeus jamaicensis). Sci. Rep., 6, 2016, 21878.
40. [40] Corman, V.M., Jores, J., Meyer, B., Younan, M., Liljander, A., Said, M.Y., et al. Antibodies against MERS coronavirus in dromedary camels, Kenya, 1992–2013. Emerg. Infect. Dis. 20:8 (2014), 1319–1322.
41. [41] Reusken, C.B., Haagmans, B.L., Müller, M.A., Gutierrez, C., Godeke, G.J., Meyer, B., et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect. Dis. 13:10 (2013), 859–866.
42. [42] Haagmans, B.L., Al Dhahiry, S.H., Reusken, C.B., Raj, V.S., Galiano, M., Myers, R., et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect. Dis. 14:2 (2014), 140–145.
43. [43] Müller, M.A., Meyer, B., Corman, V.M., Al-Masri, M., Turkestani, A., Ritz, D., et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect. Dis. 15:5 (2015), 559–564.
44. [44] Farag, E.A., Reusken, C.B., Haagmans, B.L., Mohran, K.A., Stalin Raj, V., Pas, S.D., et al. High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014. Infect. Ecol. Epidemiol., 5, 2015 Jul 15, 28305.
45. [45] Raj, V.S., Farag, E.A., Reusken, C.B., Lamers, M.M., Pas, S.D., Voermans, J., et al. Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014. Emerg. Infect. Dis. 20:8 (2014 Aug), 1339–1342.
46. [46] Sabir, J.S., Lam, T.T., Ahmed, M.M., Li, L., Shen, Y., Abo-Aba, S.E., et al. Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia. Science 351:6268 (2016), 81–84.
47. [47] Adney, D.R., van Doremalen, N., Brown, V.R., Bushmaker, T., Scott, D., de Wit, E., et al. Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg. Infect. Dis. 20:12 (2014), 1999–2005.
48. [48] Adney, D.R., Bielefeldt-Ohmann, H., Hartwig, A.E., Bowen, R.A., Infection, replication, and transmission of Middle East respiratory syndrome coronavirus in alpacas. Emerg. Infect. Dis. 22:6 (2016), 1031–1037.
49. [49] Crameri, G., Durr, P.A., Klein, R., Foord, A., Yu, M., Riddell, S., et al. Experimental infection and response to rechallenge of alpacas with Middle East respiratory syndrome coronavirus. Emerg. Infect. Dis. 22:6 (2016), 1071–1074.
50. [50] Vergara-Alert, J., van den Brand, J.M., Widagdo, W., Muñoz, M., Raj, S., et al. Livestock susceptibility to infection with Middle East respiratory syndrome coronavirus. Emerg. Infect. Dis., 15, 2017 Feb, 23(2), 10.3201/eid2302.161239 (Epub ahead of print).
51. [51] Reusken, C.B., Schilp, C., Raj, V.S., De Bruin, E., Kohl, R.H., Farag, E.A., et al. MERS-CoV infection of alpaca in a region where MERS-CoV is endemic. Emerg. Infect. Dis. 22:6 (2016), 1129–1131.
52. [52] Mohd, H.A., Al-Tawfiq, J.A., Memish, Z.A., Middle East respiratory syndrome coronavirus (MERS-CoV) origin and animal reservoir. Virol. J., 13, 2016, 87.
53. [53] Haagmans, B.L., van den Brand, J.M., Raj, V.S., Volz, A., Wohlsein, P., Smits, S.L., et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 351:6268 (2016), 77–81.
54. [54] Haagmans, B.L., van den Brand, J.M., Provacia, L.B., Raj, V.S., Stittelaar, K.J., Getu, S., et al. Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits. J. Virol. 89:11 (2015), 6131–6135.
55. [55] Chan, J.F., Yao, Y., Yeung, M.L., Deng, W., Bao, L., Jia, L., et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J. Infect. Dis. 212:12 (2015), 1904–1913.
56. [56] Johnson, R.F., Via, L.E., Kumar, M.R., Cornish, J.P., Yellayi, S., Huzella, L., et al. Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease. Virology 485 (2015), 422–430.
57. [57] Davis, W.C., Heirman, L.R., Hamilton, M.J., Parish, S.M., Barrington, G.M., Loftis, A., et al. Flow cytometric analysis of an immunodeficiency disorder affecting juvenile llamas. Vet. Immunol. Immunopathol. 74:1–2 (2000), 103–120.
58. [58] Eichler, E.E., DeJong, P.J., Biomedical applications and studies of molecular evolution: a proposal for a primate genomic library resource. Genome Res. 12:5 (2002), 673–678.
59. [59] Cowling, B.J., Park, M., Fang, V.J., Wu, P., Leung, G.M., Wu, J.T., Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015. Euro Surveill. 20:25 (2015), 7–13.
60. [60] Wu, J., Yi, L., Zou, L., Zhong, H., Liang, L., Song, T., et al. Imported case of MERS-CoV infection identified in China, May 2015: detection and lesson learned. Euro Surveill., 20(24), 2015 (pii: 21158).
61. [61] Korean Society of Infectious Diseases, Korean Society for Healthcare-associated Infection Control and Prevention, The Same Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) yet Different Outbreak Patterns and Public Health Impacts on the Far East Expert Opinion from the Rapid Response Team of the Republic of Korea. Infect. Chemother. 47:4 (2015), 247–251.
62. [62] Al-Tawfiq, J.A., Zumla, A., Memish, Z.A., Coronaviruses: severe acute respiratory syndrome coronavirus and Middle East respiratorysyndrome coronavirus in travelers. Curr. Opin. Infect. Dis. 27:5 (2014), 411–417.
63. [63] Roper, R.L., Rehm, K.E., SARS vaccines: where are we?. Expert Rev. Vaccines 8:7 (2009), 887–898.
64. [64] Honda-Okubo, Y., Barnard, D., Ong, C.H., Peng, B.H., Tseng, C.T., Petrovsky, N., Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J. Virol. 89:6 (2015), 2995–3007.
65. [65] Wirblich, C., Coleman, C.M., Kurup, D., Abraham, T.S., Bernbaum, J.G., Jahrling, P.B., et al. One-health: a safe, efficient, dual-use vaccine for humans and animals against Middle East respiratory syndrome coronavirus and rabies virus. J. Virol., 91(2), 2017 Jan 3 (pii: e02040-16).
66. [66] Simon, J.H., Claassen, E., Correa, C.E., Osterhaus, A.D., Managing severe acute respiratory syndrome (SARS) intellectual property rights: the possible role of patent pooling. Bull. World Health Organ. 83:9 (2005), 707–710.